Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Metastatic Prostate Cancer|Bone Metastases
Interventions: DRUG: Denosumab (reduced dosing)|DRUG: Denosumab (standard dosing)
Sponsor: Swiss Group for Clinical Cancer Research